A total of 598 clinical isolates of anaerobic bacteria were tested against ciprofloxacin by the agar dilution technique with 105 CFU on Wilkins-Chalgren medium. Selected strains representative of the six major genera of anaerobes relatively resistant to the quinolones were tested for interactions with ciprofloxacin in combination with clindamycin, metronidazole, cefoxitin, cefotaxime, or mezlocillin by using a checkerboard agar dilution technique. Cefotaxime-ciprofloxacin and clindamycin-ciprofloxacin were the most effective combinations, with 16% of all isolates and 44% of the Bacteroidesfragilis group isolates responding synergistically to the former combination and 9% of all isolates and 37% of Peptostreptococcus isolates responding synergistically to the latter. Occasional synergy was seen with all other antibiotic combinations except for metronidazole-ciprofloxacin. Likewise, synergism was seen with all groups of anaerobes except for Fusobacterium species. Antagonistic interactions were observed only with a Peptostreptococcus intermedius strain tested against clindamycinciprofloxacin. These data suggest that combinations of ciprofloxacin with these agents may be useful for certain resistant anaerobic infections.
Ciprofloxacin is among the most active of the aryl-fluoroquinolones, a new class of agents with broad-spectrum in vitro activity against both gram-positive and gram-negative aerobic bacteria (13, 14) as well as chlamydiae (8) , legionellae (11) , and mycobacteria (3) . However, the activity of ciprofloxacin against anaerobic bacteria is only moderate (4, 10, 12) and appears to be both medium dependent (less active in brucella medium than in Wilkins-Chalgren medium) and pH dependent (less active at pH 6 than at pH 7), but there is a minimal inoculum effect (1) . Since ciprofloxacin is likely to be used in combination with other agents in many clinical settings, it is important to ascertain the in vitro effects of such combinations. Several such studies dealing with aerobic bacteria have been published (2, 5 ; M. Bakhtiar, M. Petrou, T. R. Rogers, and S. Selwyn, in J. Ishigami, ed., Recent Advances in Chemotherapy. Antimicrobial Section 3. Proc. 14th Int. Congr. Chemother., p. [2113] [2114] 1985) , but there is a paucity of similar data regarding anaerobic bacteria. We therefore examined the in vitro interactions of ciprofloxacin with several antimicrobial agents, including clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin, against a broad category of gram-positive and gram-negative anaerobic bacteria by an agar dilution checkerboard assay.
MATERIALS AND METHODS
Bacteria. A total of 598 clinical isolates of anaerobic organisms collected at Harbor-UCLA Medical Center Hospital and Vancouver General Hospital over a 10-year period were identified to the species level by standard techniques (6) and tested for susceptibility to ciprofloxacin by the reference agar dilution procedure in Wilkins-Chalgren medium (9 Interaction studies. The two-dimensional checkerboard agar dilution tests were performed with vitamin K-heminsupplemented Wilkins-Chalgren agar. Twofold dilutions of the antibiotics were prepared, with the highest antibiotic concentration being four times the MIC for 90% of the selected isolates, as determined by agar dilution susceptibility testing (64 pLg/ml for ciprofloxacin, 16 ,ug/ml for clindamycin, 128 pLg/ml for metronidazole, cefoxitin, and cefotaxime, and 256 ,g/ml for mezlocillin). The inocula were prepared in thioglycolate broth from organisms cultured in the same medium for 48 h at 37°C and were standardized turbidimetrically to deliver ca. 105 CFU at each inoculation point. The plates were incubated for 48 h at 37°C in anaerobic jars containing 80% nitrogen, 10% hydrogen, and 10% carbon dioxide. Dilutions that permitted no visible growth were recorded. The four reference strains described earlier were included in each experiment. As a control measure for bacterial growth, additional plates without antibiotics were inoculated and incubated under similar conditions. f Includes S. intermedius (16 strains) and S. constellatus (5 strains). 8 Includes C. inocuum (3 strains), C. cadaveris (2 strains), C. ramosum (2 strains), C. glycolicum (1 strain), C. haemolyticum (1 strain), C. lentoputrescens (1 strain), C. septicum (1 strain), and C. bifermentans (1 strain).
h Includes E. lentum (11 strains), E. aerofaciens (6 strains), E. tenue (1 strain), E. limosum (1 strain) , and E. alactolyticum (1 strain Streptococcus ( (5) Total (45) 4 (9) 1(2)
a -, Neither synergy nor antagonism was demonstrated.
strain), while those responding synergistically to ciprofloxstrains either had a reduced susceptibility to ciprofloxacin or acin-cefotaxime and ciprofloxacin-mezlocillin combinations were clearly resistant. All of the antibiotics chosen for were predominantly Bacteroides species (four and three combination with ciprofloxacin had some activity against strains, respectively).
anaerobes. Because of the differing mechanisms of action of Antagonistic combinations with ciprofloxacin were found these agents and the differing patterns of susceptibility of only with clindamycin in a single strain (S. intermedius anaerobes to these agents, it was speculated that distinctive 2186F) ( Table 2 ). For four other isolates the maximum XFIC patterns of interaction for these agents in combination with indices were >2 but <4 in combinations with either clindaciprofloxacin might be observed. Our data support this mycin or cefoxitin. All metronidazole-ciprofloxacin interachypothesis. Of particular interest was that 44% of the B. tions were either additive or indifferent.
fragilis group strains responded synergistically to the cefotaxime-ciprofloxacin combination, and there was an overall DISCUSSION additive effect for the remaining strains. In contrast, 20% of non-B. fragilis Bacteroides species and 37% of PeptoThe in vitro susceptibility data reported here are similar to streptococcus species responded synergistically to the those of other investigators (4, 10, 12) and demonstrate that mezlocillin-ciprofloxacin and clindamycin-ciprofloxacin ciprofloxacin is only moderately active against anaerobic combinations, respectively. In all cases, synergy occurred at bacteria at clinically achievable concentrations (7) . Only concentrations easily achievable in serum with these antibi-40% of 598 clinical isolates tested were inhibited at 1 p.g/ml, otics. Although the number of strains studied was relatively while 78% were inhibited at 4 p.g/ml (data not shown). Since small, the frequency of synergistic combinations with these ciprofloxacin is likely to be used in combination with other antibiotics was well above the 1% level that Haller considagents, the possibility of either synergistic or antagonistic ered as expected "background activity" due to methodologinteractions in these combinations against anaerobes is clinical variations of the checkerboard assay (5). ically important and was a major reason for this investigaReassuringly, antagonistic interactions with ciprofloxacin, tion.
defined here as a maximum IFIC index of >4, were rare in Representative strains from each of six major genera of our study. Such an interaction occurred only once in the 225 anaerobes were selected for study. The majority of these individual combinations tested. This single instance involved a strain of S. intermedius (an organism not usually considered a strict anaerobe) and the clindamycin-ciprofloxacin combination.
The clinical relevance of these in vitro interactions against anaerobic bacteria will require further study. Since anaerobic bacteria in polymicrobial infections often disappear during therapy despite in vitro resistance to the antimicrobial agents administered, the best method for performing clinically predictive susceptibility tests with these organisms remains unknown. Nevertheless, our data indicate that ciprofloxacin does not appear to antagonize the activity of most classes of antibiotics commonly used in the treatment of anaerobic infections, and combinations of ciprofloxacin with these agents may prove useful for certain resistant anaerobic infections.
